Philips debuts Gyroscan CV
Philips Medical Systems has formally rolled out Gyroscan CV, the vendor’s cardiovascular MRI system. Initially highlighted at the 1998 RSNA meeting (SCAN Special Report 1/99), Gyroscan CV employs a 1.5-tesla open magnet design and features
Philips Medical Systems has formally rolled out Gyroscan CV, the vendors cardiovascular MRI system. Initially highlighted at the 1998 RSNA meeting (SCAN Special Report 1/99), Gyroscan CV employs a 1.5-tesla open magnet design and features optimized cardiovascular software, a five-element cardiac coil, and the firms EasyVision diagnostic workstation.
Gyroscan CV can provide information about cardiac anatomy and pathology; ventricular function; valvular function; wall motion, wall thickness, and thickening; myocardial perfusion; and coronary angiography, according to Philips of Best, The Netherlands. Philips believes that by using Gyroscan CV, healthcare institutions can reduce the need for x-ray and nuclear medicine scans, as well as contrast media.
One of the available options on Gyroscan CV is MobiTrak, an automated peripheral vascular angiography tool. MobiTrak, first shown at the 1996 RSNA meeting, combines contrast-enhanced 3-D MR angiography (MRA) with rapid, automatic table movement between successive coronal acquisitions. The result is high quality images from the abdominal aorta to the feet with a scan time of three to four minutes, according to Philips.
Another MRA technique, BolusTrak, provides real-time display and visual detection for contrast-enhanced procedures. With BolusTrak, the angiography acquisition can be precisely synchronized to the arrival of the bolus, according to Philips.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
